Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2025-08-19 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物关于公司2025年度提质增效重回报专项行动方案的半年度评估报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '半年度评估报告' which translates to 'Half-Year Assessment Report' related to the company's 2025 special action plan for quality improvement and efficiency enhancement. It contains detailed financial data for the first half of 2025, including revenue, net profit, assets, and equity figures. It also discusses operational achievements, governance improvements, investor relations, and management compensation. The presence of substantive financial data and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is 3838 characters, which is relatively short but contains actual financial data and detailed narrative, so it is not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2025
2025-08-19 Chinese
安旭生物2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled '2025 年半年度报告摘要' which translates to '2025 Semi-Annual Report Summary'. It contains financial data for the half-year period, including total assets, net profit, revenue, and shareholder information. It explicitly states it is a half-year report summary and references the full half-year report for detailed information. The document length is 3191 characters, which is relatively short but contains substantive financial data and analysis for the half-year period. It is not merely an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-19 Chinese
安旭生物2025年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled '2025 年第一次临时股东大会会议资料' which translates to '2025 First Extraordinary General Meeting (EGM) Materials'. It contains detailed agenda items, meeting instructions, and proposals for shareholder voting, including board elections and amendments to company bylaws. The content is clearly materials prepared for and shared at a shareholders' meeting, including procedural rules, agenda, and detailed proposals for shareholder consideration. There is no financial data or earnings information, nor is it a transcript or announcement of results. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during a general meeting. Although it is an extraordinary meeting, the category AGM-R covers such meeting materials. The document length is over 6,000 characters, indicating it is the actual meeting materials, not just an announcement of a report. Therefore, the correct classification is AGM-R with high confidence.
2025-08-18 Chinese
独立董事工作细则（202508）
Governance Information Classification · 95% confidence The document is titled '独立董事工作细则' which translates to 'Independent Director Work Rules' for 杭州安旭生物科技股份有限公司. It details the qualifications, duties, responsibilities, and procedural rules for independent directors within the company. The content focuses on governance structure, director independence, committee roles, and related governance practices. There is no financial data, audit information, or report publication announcement. The document is a governance-related internal regulation or guideline. Therefore, it fits best under Governance Information (CGR). The document length (8342 characters) and detailed content support this classification with high confidence.
2025-08-06 Chinese
董事会战略委员会工作细则（202508）
Governance Information Classification · 95% confidence The document is titled as the "Board of Directors Strategic Committee Work Rules" of Hangzhou Anxu Biotechnology Co., Ltd., revised in August 2025. It details the committee's responsibilities, organizational structure, meeting procedures, and governance rules. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, no capital changes, or other report types. The document is a governance-related internal rules document for a board committee. Therefore, it fits the category of Governance Information (CGR). The document length is 3571 characters, which is consistent with a detailed governance document rather than a brief announcement or report publication notice.
2025-08-06 Chinese
杭州安旭生物科技股份有限公司章程（202508）
Governance Information Classification · 100% confidence The document is titled "公司章程" which translates to "Company Articles of Association" or "Company Bylaws." It contains detailed provisions about the company's organizational structure, shareholder rights, board of directors, management, financial accounting, profit distribution, auditing, and other governance-related matters. It references relevant laws such as the Company Law, Securities Law, and listing rules of the Shanghai Stock Exchange. The content is focused on the internal rules and governance framework of the company rather than financial results, audit opinions, or meeting announcements. It is a governance document that sets out the company's internal rules and board structure. Therefore, the document fits the category of Governance Information (CGR). The document length is substantial (15,000 characters), indicating it is the full text of the governance document, not just an announcement or summary.
2025-08-06 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.